Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medication lumateperone as adjunctive to antidepressant therapy in the treatment of patients with major depressive disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the December issue of the Journal.

00:48 Durgam interview
03:09 Mechanism of action
04:44 Patient-reported outcomes
06:31 Immediate clinical implications
07:32 Limitations
08:08 Further research
09:25 Kalin interview
09:38 Durgam et al.
13:09 Lin et al.
17:22 Brodsky et al.

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial

American Journal of Psychiatry Audio